News
New CEO announced
Klas Palin
2026-02-06
07:33 CET
Jonas Sohlman stepped down as CEO in an announcement made after market close yesterday, with the role transitioning to newly appointed Carl-Johan Dalsgaard, effective immediately. At this stage, no further information has been disclosed, and we look to the upcoming Q4 2025 report, which should provide an opportunity for the new CEO to outline his strategic priorities and perspective on the company’s growth opportunities.
What’s new? A change in the leadership team was announced yesterday after market close, with Jonas Sohlman stepping down from his role as CEO after more than two years at Intervacc. The board has appointed Carl-Johan Dalsgaard as the new CEO, with the transition effective immediately.
Who’s stepping in? Incoming CEO Carl-Johan Dalsgaard has a strong clinical and scientific background, with more than 25 years of industry experience in pharmaceutical and biotech drug development. Since 2000, he has been active as a venture partner at HealthCap, Intervacc’s largest shareholder, which suggests a deep prior understanding of the company and its investment case. His profile appears well suited to the role, with previous CEO experience across several biotechnology companies, including Vicore Pharma, Biolipox and Affibody.
What’s next? Intervacc is approaching the release of its Q4 2025 results within the next two weeks, and we look for the report to demonstrate continued strong revenue growth, underpinning further momentum in its European market activities. While leadership changes with immediate effect can introduce a degree of short-term uncertainty, the reasons for the transition have not been disclosed. As such, the upcoming report will be an important opportunity to demonstrate continued operational progress and for the new CEO to outline his strategic priorities and perspective on the company’s growth opportunities.